GSK resubmitted an NDA for tebipenem pivoxil hydrobromide to the FDA for cUTI treatment, including pyelonephritis. The phase 3 PIVOT-PO trial showed tebipenem HBr's noninferiority to ...
Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...
Rucaparib is now approved for BRCA mutation-associated mCRPC patients post-androgen receptor therapy, without prior chemotherapy requirement. The TRITON3 trial showed significant improvement in ...
Early treatment intensification with ADT and ARPIs is now standard for mCSPC, with patient-specific factors guiding therapy selection. Enzalutamide, apalutamide, abiraterone, and darolutamide are key ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
The Revi System, an implantable tibial neuromodulation device, received FDA 510(k) clearance for its enhanced version, improving urgency urinary incontinence treatment. The OASIS trial confirmed the ...
As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025. Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the ...
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
In this interview, Seth P. Lerner, MD, discusses current recommendations for managing patients during the BCG shortage, what the FDA is doing to resolve the problem, and a SWOG trial testing a new ...
Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback